Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease

An historical account

Udaya S. Tantry, Elisabeth Mahla, Martin G. Gesheff, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

The pivotal roles of platelets in physiological hemostasis and pathological thrombosis at the site of plaque rupture are well established. The latter roles provide the fundamental basis for the most widely implemented pharmacologic management of coronary artery disease-dual antiplatelet therapy with aspirin to inhibit platelet thromboxane A2 generation, and a P2Y12 receptor inhibitor to prevent adenosine diphosphate (ADP)-induced platelet activation. Although suboptimal pharmacodynamic efficacy, also described as high on-treatment platelet reactivity to ADP, has been associated with greater risk for post-stenting ischemic event occurrence, enhanced responsiveness is associated with higher risk for bleeding in selected patients. In this review article, we aim to provide an historical account of the one and a half century long journey starting with the first description of platelets through the first report of ex vivo measurement of ADP-induced platelet aggregation, the first demonstration of an association between ADP-induced platelet aggregation and post-stenting ischemic event occurrence, and finally to the most recent description of a 'therapeutic window' concept for P2Y12 receptor inhibitor therapy.

Original languageEnglish (US)
Pages (from-to)1547-1556
Number of pages10
JournalExpert Review of Cardiovascular Therapy
Volume11
Issue number11
DOIs
StatePublished - 2013

Fingerprint

Adenosine Diphosphate
Coronary Artery Disease
Blood Platelets
Platelet Aggregation
Thromboxane A2
Platelet Activation
Therapeutics
Hemostasis
Aspirin
Rupture
Thrombosis
Hemorrhage

Keywords

  • clopidogrel
  • coronary artery disease
  • dual antiplatelet therapy
  • high platelet reactivity
  • P2Y receptor
  • personalized antiplatelet therapy
  • platelet
  • platelet function assays

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease : An historical account. / Tantry, Udaya S.; Mahla, Elisabeth; Gesheff, Martin G.; Gurbel, Paul A.

In: Expert Review of Cardiovascular Therapy, Vol. 11, No. 11, 2013, p. 1547-1556.

Research output: Contribution to journalArticle

Tantry, Udaya S. ; Mahla, Elisabeth ; Gesheff, Martin G. ; Gurbel, Paul A. / Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease : An historical account. In: Expert Review of Cardiovascular Therapy. 2013 ; Vol. 11, No. 11. pp. 1547-1556.
@article{67bfe4e9c7274074853ba225a3b8804c,
title = "Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: An historical account",
abstract = "The pivotal roles of platelets in physiological hemostasis and pathological thrombosis at the site of plaque rupture are well established. The latter roles provide the fundamental basis for the most widely implemented pharmacologic management of coronary artery disease-dual antiplatelet therapy with aspirin to inhibit platelet thromboxane A2 generation, and a P2Y12 receptor inhibitor to prevent adenosine diphosphate (ADP)-induced platelet activation. Although suboptimal pharmacodynamic efficacy, also described as high on-treatment platelet reactivity to ADP, has been associated with greater risk for post-stenting ischemic event occurrence, enhanced responsiveness is associated with higher risk for bleeding in selected patients. In this review article, we aim to provide an historical account of the one and a half century long journey starting with the first description of platelets through the first report of ex vivo measurement of ADP-induced platelet aggregation, the first demonstration of an association between ADP-induced platelet aggregation and post-stenting ischemic event occurrence, and finally to the most recent description of a 'therapeutic window' concept for P2Y12 receptor inhibitor therapy.",
keywords = "clopidogrel, coronary artery disease, dual antiplatelet therapy, high platelet reactivity, P2Y receptor, personalized antiplatelet therapy, platelet, platelet function assays",
author = "Tantry, {Udaya S.} and Elisabeth Mahla and Gesheff, {Martin G.} and Gurbel, {Paul A.}",
year = "2013",
doi = "10.1586/14779072.2013.839382",
language = "English (US)",
volume = "11",
pages = "1547--1556",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease

T2 - An historical account

AU - Tantry, Udaya S.

AU - Mahla, Elisabeth

AU - Gesheff, Martin G.

AU - Gurbel, Paul A.

PY - 2013

Y1 - 2013

N2 - The pivotal roles of platelets in physiological hemostasis and pathological thrombosis at the site of plaque rupture are well established. The latter roles provide the fundamental basis for the most widely implemented pharmacologic management of coronary artery disease-dual antiplatelet therapy with aspirin to inhibit platelet thromboxane A2 generation, and a P2Y12 receptor inhibitor to prevent adenosine diphosphate (ADP)-induced platelet activation. Although suboptimal pharmacodynamic efficacy, also described as high on-treatment platelet reactivity to ADP, has been associated with greater risk for post-stenting ischemic event occurrence, enhanced responsiveness is associated with higher risk for bleeding in selected patients. In this review article, we aim to provide an historical account of the one and a half century long journey starting with the first description of platelets through the first report of ex vivo measurement of ADP-induced platelet aggregation, the first demonstration of an association between ADP-induced platelet aggregation and post-stenting ischemic event occurrence, and finally to the most recent description of a 'therapeutic window' concept for P2Y12 receptor inhibitor therapy.

AB - The pivotal roles of platelets in physiological hemostasis and pathological thrombosis at the site of plaque rupture are well established. The latter roles provide the fundamental basis for the most widely implemented pharmacologic management of coronary artery disease-dual antiplatelet therapy with aspirin to inhibit platelet thromboxane A2 generation, and a P2Y12 receptor inhibitor to prevent adenosine diphosphate (ADP)-induced platelet activation. Although suboptimal pharmacodynamic efficacy, also described as high on-treatment platelet reactivity to ADP, has been associated with greater risk for post-stenting ischemic event occurrence, enhanced responsiveness is associated with higher risk for bleeding in selected patients. In this review article, we aim to provide an historical account of the one and a half century long journey starting with the first description of platelets through the first report of ex vivo measurement of ADP-induced platelet aggregation, the first demonstration of an association between ADP-induced platelet aggregation and post-stenting ischemic event occurrence, and finally to the most recent description of a 'therapeutic window' concept for P2Y12 receptor inhibitor therapy.

KW - clopidogrel

KW - coronary artery disease

KW - dual antiplatelet therapy

KW - high platelet reactivity

KW - P2Y receptor

KW - personalized antiplatelet therapy

KW - platelet

KW - platelet function assays

UR - http://www.scopus.com/inward/record.url?scp=84887368212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887368212&partnerID=8YFLogxK

U2 - 10.1586/14779072.2013.839382

DO - 10.1586/14779072.2013.839382

M3 - Article

VL - 11

SP - 1547

EP - 1556

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 11

ER -